Randomised placebo controlled trial of Pramipexole addition to mood stabilisers for treatment resistant bipolar depression (PAX-BD)

PAX-BD is a major trial examining a novel treatment for bipolar disorder, funded by the National Institute for Health Research’s (NIHR) Health Technology Assessment (HTA) Board.  The study examines the effectiveness and safety of a drug, pramipexole which is currently used to treat Parkinson’s Disease, for patients with bipolar disorder who are depressed and have not responded to NICE recommended treatments.   For more information click here.